The stock reaction is likely to be muted as the filing contains no clinical data readouts or near-term catalysts. Monitor upcoming SID meeting in May 2026 for preclinical data presentation and track enrollment progress in the ADAPTIVE trial for potential acceleration of the timeline.
IMA drugs
IMA drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 10 $6.07entry
- T+1 · 8mo ago −0.99%α −0.88% · $6.01
- T+5 · 8mo ago −0.82%α +0.08% · $6.02
- T+20 · 7mo ago −24.71%α −24.56% · $4.57
- T+60 · 6mo ago −10.21%α −21.90% · $5.45
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
ImageneBio reported its Q4 and full-year 2025 financial results, highlighting a strong cash position of $135.3 million post-merger and ongoing Phase 2b ADAPTIVE trial for IMG-007 in atopic dermatitis. While R&D spending decreased slightly, G&A expenses more than doubled due to merger-related and personnel costs, leading to a wider net loss. No revenue or earnings guidance was provided, and the company remains in clinical development with no near-term commercial catalysts.
Key Financial Metrics
Key Facts
- Ended 2025 with $135.3 million in cash, up from $12.1 million in 2024, due to a reverse merger and $75 million private placement.
- R&D expenses decreased to $3.3M in Q4 2025 from $3.8M in Q4 2024.
- G&A expenses rose to $5.2M in Q4 2025 from $2.4M in Q4 2024, driven by merger costs and stock-based compensation.
- Net loss widened to $6.9M in Q4 2025 from $4.8M in Q4 2024.
- Full-year 2025 net loss was $45.3M vs. $36.6M in 2024; license revenue declined to $800K from $3.5M.
- IMG-007 Phase 2b trial ongoing with topline data expected in 2027; protocol amendment submitted to expand dosing regimens.
- No safety concerns reported; no cases of pyrexia, ulcers, or malignancies observed.
Financial Impact
License revenue declined 77% YoY to $800K; full-year net loss increased 24% to $45.3M. Cash position strengthened to $135.3M, sufficient to fund operations into late-stage trials.
Risk Factors
- Clinical development risk: IMG-007 is still in Phase 2b with topline data not expected until 2027.
- Revenue concentration: License revenue dropped sharply from $3.5M to $800K, indicating reliance on non-core, one-time income sources.
- Increasing G&A costs: Rising administrative expenses post-merger could pressure cash runway if not managed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3252746 |
Track record
10 reports on IMA
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +27.94% at T+60 after the Aug 7, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $3.50 Now $3.20 −8.57% settles Feb 12
- Nov 9, 20267d ago 8-K Neutral 4/10 Entry $3.81 Now $3.20 −16.01% settles Feb 8
- Aug 7, 202614w ago EFFECT Bearish 5/10 Entry $5.69 to $4.10 Now $3.20 +43.76% ▲ +27.94% +25.81% vs SPY
- Jun 26, 202620w ago 8-K Neutral 3/10 Entry $6.07 to $4.85 Now $3.20 −47.28% ▼ −20.10% −24.48% vs SPY
- Apr 30, 202628w ago DEFA14A Neutral 3/10 Entry $5.66 to $5.76 Now $3.20 −43.46% ▲ +1.77% −1.30% vs SPY
- Apr 13, 202631w ago 8-K Bearish 6/10 Entry $6.05 to $5.93 Now $3.20 +47.11% ▲ +2.07% +10.99% vs SPY
- Apr 13, 202631w ago Press Release Bearish 6/10 Entry $6.05 to $5.93 Now $3.20 +47.11% ▲ +2.07% +10.99% vs SPY
- Apr 6, 202632w ago EFFECT Neutral 3/10 Entry $4.55 to $5.77 Now $3.20 −29.67% ▲ +26.81% +13.34% vs SPY
- Mar 17, 202634w ago Press Release Neutral 3/10 Entry $5.83 to $5.71 Now $3.20 −45.06% ▼ −1.97% −13.50% vs SPY
- Mar 10, 202635w ago Press Release Neutral 4/10 Viewing Entry $6.07 to $5.45 Now $3.20 −47.28% ▼ −10.21% −21.90% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers